Value comparison
Value stocks: strong cash flow or a cleaner business?
Value stocks split between CVS’s cash yield and EPAM’s stronger returns, while CNP and Celanese lean on investment or recovery. The catch: the cheapest-looking metrics come with very different balance-sheet and earnings tests.
Why these companies
- CVS qualifies through its Undervalued verdict and 10.4% TTM FCF yield, though its low operating margin and high net debt make cash generation and insurance performance central tests.
- CNP qualifies as a regulated energy-delivery business with 8.3% revenue growth and a 22.6% operating margin, but negative TTM FCF and substantial net debt put capital funding at the heart of its case.
- Celanese qualifies through its Undervalued verdict and 14.0% TTM FCF yield, while declining revenue, negative operating margin and negative ROIC make a durable operating recovery necessary to support the case.
- EPAM qualifies through its 15.4% revenue growth, 11.1% ROIC and net-cash position, although its Fairly Valued verdict leaves limited distance between its price and fair value.
The numbers
| Company | Price | Fair value | Upside | Verdict | Risk | Market cap | P/E (TTM) | FCF yield (TTM) | Revenue growth | Operating margin | ROIC | Net debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVS HEALTH CorpCVS | USD 87.17 | USD 104.00 | +19.3% | Undervalued | Elevated risk | USD 113.1B | 23.1x | 10.4% | 7.8% | 1.2% | 2.6% | USD 55.3B |
| CENTERPOINT ENERGY INCCNP | USD 38.70 | USD 36.10 | -6.7% | Fairly Valued | Elevated risk | USD 24.1B | 22.5x | -11.1% | 8.3% | 22.6% | 5.3% | USD 20.5B |
| Celanese CorpCE | USD 44.99 | USD 60.00 | +33.4% | Undervalued | High risk | USD 5.1B | — | 14.0% | -7.1% | -8.2% | -3.7% | USD 11.3B |
| EPAM Systems, Inc.EPAM | USD 112.94 | USD 110.55 | -2.1% | Fairly Valued | Elevated risk | USD 5.6B | 14.6x | 8.7% | 15.4% | 9.5% | 11.1% | USD -1.3B |
Fair values and metrics are from each company's latest SageNoodle report; prices are the latest quotes on file (Fri, 09 Oct 2026 19:31:19 GMT). Each company is valued in its own quote currency.
CVS offers the clearest cash-yield case, with an insurance recovery to prove.
At USD 87.85, CVS is marked Undervalued against a USD 104 fair value; its 10.4% TTM FCF yield sits beside 1.2% operating margin, 2.6% ROIC and USD 55.3B net debt. The research report says second-quarter improvement in Health Care Benefits was complicated by the absence of a prior-year reserve and favorable development of earlier claims estimates. That makes the yield appealing, but the earnings recovery—not the headline rating—is what must hold up.
What breaks itMedical-cost volatility can reverse the insurance improvement, and pharmacy reimbursement pressure remains another drag. CVS also has to manage its connected insurance, PBM, pharmacy and care businesses while carrying substantial net debt.
Full report: CVS Health stock: GLP-1 access is a strategy, not today’s catalyst (29 Sept 2026)
CNP suits readers who can live with a utility’s capital bill arriving before its growth.
CNP’s USD 36.62 price is close to its USD 36.1 fair value, while its TTM FCF yield is -11.1% and net debt is USD 20.5B. The research report describes a large-load pipeline and an expanded capital plan, but submitted projects and expected eligibility are not energized customers or earned returns. The economic hinge is whether approvals, construction and regulated recovery turn that investment into earnings before financing costs erode the benefit.
What breaks itIf load approvals or connections slip, or regulators do not allow timely recovery, spending and financing costs can outrun the return. Negative TTM free cash flow means the plan cannot be judged on demand figures alone.
Full report: CenterPoint Energy stock: Houston’s load boom comes with a $66.7B bill (28 Sept 2026)
Celanese has the strongest stated value gap—and the least forgiving operating evidence.
CE’s USD 45.92 price is below its USD 60 fair value, but its -7.1% revenue growth, -8.2% operating margin, -3.7% ROIC and USD 11.3B net debt make the recovery case consequential. The research report describes a Q2 adjusted-earnings rebound, but management expects Q3 adjusted EPS of approximately $1.35 to $1.75, below Q2’s $2.45. The 14.0% TTM FCF yield and fair-value gap do not remove the need for earnings and cash generation to persist long enough to ease the debt burden.
What breaks itA softer quarter that becomes a lasting earnings setback would weaken both cash generation and the deleveraging case. Management’s cost-savings expectations and forward guidance are not completed results.
Full report: Celanese stock: a sharp Q2 rebound still has a softer quarter ahead (28 Sept 2026)
EPAM pairs growth and net cash with a modest fair-value gap.
EPAM’s USD 107.55 price is close to its USD 110.55 fair value; revenue growth is 15.4%, operating margin is 9.5%, ROIC is 11.1%, and net debt is USD -1.3B. The research report shows FY2025 revenue growth alongside an operating margin below earlier years, and quarterly free cash flow was negative in both Q1 and Q2 FY2026. This is the cleaner balance-sheet profile in the group, but customers’ spending and the conversion of services revenue into profit and cash still matter.
What breaks itFurther margin pressure or persistently weak cash generation would challenge the earnings base behind a near-fair-value share price. The research report says client spending and delivery utilization matter, but does not quantify current commitments or utilization.
Full report: EPAM Systems stock: the 1.2% rise has no verified catalyst (28 Sept 2026)
Which one fits you
CVS fits a reader willing to accept insurance and balance-sheet risk in exchange for a high stated cash yield and a discounted fair-value assessment. CNP is for someone comfortable with utility investment cycles and waiting for project approvals and rate recovery to catch up with spending; Celanese is for a reader who can tolerate a more demanding cyclical recovery case. EPAM better fits someone prioritizing growth, returns and net cash over a large stated valuation gap, while accepting that its margin and quarterly cash-flow record need watching.